索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]黄帅 白津宇 周静 高峰 薛万腾.NLRP3炎性小体与心血管疾病[J].国际心血管病杂志,2020,01:32-36.
点击复制

NLRP3炎性小体与心血管疾病(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2020年01期
页码:
32-36
栏目:
综述
出版日期:
2020-01-14

文章信息/Info

Title:
-
作者:
黄帅 白津宇 周静 高峰 薛万腾
716000延安大学附属医院心内科
Author(s):
-
关键词:
核苷酸结合寡聚化结构域样受体蛋白3炎性小体;  心血管疾病;  治疗策略
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2020.01.008
文献标识码:
-
摘要:
核苷酸结合寡聚化结构域样受体蛋白3(NLRP3)炎性小体是由NLRP3、衔接蛋白凋亡相关斑点样蛋白(ASC)和效应蛋白胱天蛋白酶(caspase)-1组成的多蛋白复合体,广泛存在于人体的各种免疫细胞及非免疫细胞,参与体内炎性反应。研究表明,NLRP3炎性小体在心血管疾病的发生发展中发挥重要作用。NLRP3炎性小体及其活化产物的拮抗剂可用于心血管疾病的预防及治疗。该文介绍NLRP3炎性小体与心血管疾病的关系以及与NLRP3炎性小体相关的心血管疾病的治疗策略。
Abstract:
-

参考文献/References

[ 1 ]Takahashi M. NLRP3 inflammasome as a novel player in myocardial infarction[J]. Int Heart J, 2014, 55(2):101-105.
[ 2 ]Mariathasan S, Newton K, Monack DM, et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf[J]. Nature, 2004, 430(6996):213-218.
[ 3 ]Chatterjee S, Das S. P2X7 receptor as a key player in oxidative stress-driven cell fate in nonalcoholic steatohepatitis [J]. Oxid Med Cell Longev, 2015, 2015:172493.
[ 4 ]Orlowski GM, Colbert JD, Sharma S, et al. Multiple cathepsins promote pro-IL-1β synthesis and NLRP3-mediated IL-1β activation[J]. J Immunol, 2015, 195(4):1685-1697.
[ 5 ]Wang X, Wang S, Hu C, et al. A new pharmacological effect of levornidazole: inhibition of NLRP3 inflammasome activation[J]. Biochem Pharmacol, 2015, 97(2):178-188.
[ 6 ]Murakami T, Ockinger J, Yu J, et al. Critical role for calcium mobilization in activation of the NLRP3 inflammasome[J]. Proc Natl Acad Sci U S A, 2012, 109(28):11282-11287.
[ 7 ]Zhou R, Tardivel A, Thorens B, et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation[J]. Nat Immunol, 2010, 11(2):136-140.
[ 8 ]He Y, Zeng MY, Yang D, et al. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux [J]. Nature, 2016, 530(7590):354-357.
[ 9 ]Meunier E, Dick MS, Dreier RF, et al. Caspase-11 activation requires lysis of pathogen-containing vacuoles by IFN-induced GTPases[J]. Nature, 2014, 509(750):366-370.
[10]Schmid-Burgk JL, Chauhan D, Schmidt T, et al. A genome-wide CRISPR(clustered regularly interspaced short palindromic repeats)screen identifies NEK7 as an essential component of NLRP3 inflammasome activation[J]. J Biol Chem, 2016, 291(1):103-109.
[11]Zhai Y, Ao L, Cleveland JC, et al. Toll-like receptor 4 mediates the inflammatory responses and matrix protein remodeling in remote non-ischemic myocardium in a mouse model of myocardial ischemia and reperfusion[J]. PLoS One, 2015, 10(3):e0121853.
[12]Sano S, Oshima K, Wang Y, et al. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 inflammasome[J]. J Am Coll Cardiol, 2018, 71(8):875-886.
[13]Bracey NA, Gershkovich B, Chun J, et al. Mitochondrial NLRP3 protein induces reactive oxygen species to promote Smad protein signaling and fibrosis independent from the inflammasome[J]. J Biol Chem, 2014, 289(28):19571-19584.
[14]Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases[J]. Blood, 2011, 117(14):3720-3732.
[15]Van Tassell BW, Arena RA, Toldo S, et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure[J]. PLoS One, 2012, 7(3):e33438.
[16]Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management[J]. Circ J, 2015, 79(3):495-502.
[17]Yao C, Veleva T, Scott L, et al. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation[J]. Circulation, 2018, 138(20):2227-2242.
[18]Haque S, Lan X, Wen H, et al. HIV promotes NLRP3 inflammasome complex activation in murine HIV-associated nephropathy[J]. Am J Pathol, 2016, 186(2):347-358.
[19]Afrasyab A, Qu P, Zhao Y, et al. Correlation of NLRP3 with severity and prognosis of coronary atherosclerosis in acute coronary syndrome patients[J]. Heart Vessels, 2016, 31(8):1218-1229.
[20]Bando S, Fukuda D, Soeki T, et al. Expression of NLRP3 in subcutaneous adipose tissue is associated with coronary atherosclerosis[J]. Atherosclerosis, 2015, 242(2):407-414.
[21]Hoseini Z, Sepahvand F, Rashidi B, et al. NLRP3 inflammasome: its regulation and involvement in atherosclerosis[J]. J Cell Physiol, 2018, 233(3):2116-2132.
[22]Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals[J]. Nature, 2010, 464(7293):1357-1361.
[23]Jiang Y, Wang M, Huang K, et al. Oxidized low-density lipoprotein induces secretion of interleukin-1β by macrophages via reactive oxygen species-dependent NLRP3 inflammasome activation[J]. Biochem Biophys Res Commun, 2012, 425(2):121-126.
[24]Kirii H, Niwa T, Yamada Y, et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice[J]. Arterioscler Thromb Vasc Biol, 2003, 23(4):656-660.
[25]黄丛富. 肾脏中NLRP3炎性体在孕期LPS刺激致子代大鼠高血压中的作用研究[D]. 洛阳:河南科技大学, 2017.
[26]Qi J, Yu XJ, Shi XL, et al. NF-κB blockade in hypothalamic paraventricular nucleus inhibits high-salt-induced hypertension through NLRP3 and caspase-1[J]. Cardiovasc Toxicol, 2016, 16(4):345-354.
[27]Krishnan SM, Dowling JK, Ling YH, et al. Inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induced hypertension in mice[J]. Br J Pharmacol, 2016, 173(4):752-765.
[28]Bracey NA, Beck PL, Muruve DA, et al. The NLRP3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1β[J]. Exp Physiol, 2013, 98(2):462-472.
[29]Zhang W, Xu X, Kao R, et al. Cardiac fibroblasts contribute to myocardial dysfunction in mice with sepsis: the role of NLRP3 inflammasome activation[J]. PLoS One, 2014, 9(9):e107639.
[30]Wang Y, Gao B, Xiong S. Involvement of NLRP3 inflammasome in CVB3-induced viral myocarditis[J]. Am J Physiol Heart Circ Physiol, 2014, 307(10):H1438-H1447.
[31]Tschöpe C, Müller I, Xia Y, et al. NOD2(nucleotide-binding oligomerization domain 2)is a major pathogenic mediator of coxsackievirus B3-induced myocarditis[J]. Circ Heart Fail, 2017, 10(9):e003870.
[32]Youm YH, Grant RW, Mccabe LR, et al. Canonical NLRP3 inflammasome links systemic low-grade inflammation to functional decline in aging[J]. Cell Metab, 2013, 18(4):519-532.
[33]Dinarello CA. Van der Meer JW. Treating inflammation by blocking interleukin-1 in humans[J]. Semin Immunol, 2013, 25(6):469-484.
[34]Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase Ⅱb randomized, placebo-controlled trial[J]. Circulation, 2012, 126(23):2739-2748.
[35]Rajamäki K, Lappalainen J, Oörni K, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation[J]. PLoS One, 2010, 5(7):e11765.
[36]Gage J, Hasu M, Thabet M, et al. Caspase-1 deficiency decreases atherosclerosis in apolipoprotein E-null mice[J]. Can J Cardiol, 2012, 28(2):222-229.
[37]Alfaidi M, Wilson H, Daigneault M, et al. Neutrophil elastase promotes interleukin-1β secretion from human coronary endothelium[J]. J Biol Chem, 2015, 290(40):24067-24078.
[38]Chamberlain J, Evans D, King A, et al. Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice[J]. Am J Pathol, 2006, 168(4):1396-1403.
[39]Zheng F, Xing S, Gong Z, et al. Silence of NLRP3 suppresses atherosclerosis and stabilizes plaques in apolipoprotein E-deficient mice[J]. Mediators Inflamm, 2014, 2014:507208.
[40]Abderrazak A, Couchie D, Mahmood DF, et al. Anti-inflammatory and antiatherogenic effects of the NLRP3 inflammasome inhibitor arglabin in ApoE2.Ki mice fed a high-fat diet[J]. Circulation, 2015, 131(12):1061-1070.
[41]Van der Heijden T, Kritikou E, Venema W, et al. NLRP3 inflammasome inhibition by MCC950 reduces atherosclerotic lesion development in apolipoprotein E-deficient mice[J]. Arterioscler Thromb Vasc Biol, 2017, 37(8):1457-1461.
[42]Wang L, Chen Y, Li X, et al. Enhancement of endothelial permeability by free fatty acid through lysosomal cathepsin B-mediated Nlrp3 inflammasome activation[J]. Oncotarget, 2016, 7(45):73229-73241.
[43]Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance[J]. Cell Metab, 2012, 15(5):635-645.
[44]Yan Y, Jiang W, Liu L, et al. Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome[J]. Cell, 2015, 160(1/2):62-73.
[45]Sokolowska M, Chen LY, Liu Y, et al. Prostaglandin E2 inhibits NLRP3 inflammasome activation through EP4 receptor and intracellular cyclic AMP in human macrophages[J]. J Immunol, 2015, 194(11):5472-5487.
[46]Youm YH, Nguyen KY, Grant RW, et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease[J]. Nat Med, 2015, 21(3):263-269.
[47]Huang Y, Jiang H, Chen Y, et al. Tranilast directly targets NLRP3 to treat inflammasome-driven diseases[J]. EMBO Mol Med, 2018, 10(4):e8689.
[48]Jiang H, He H, Chen Y, et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders[J]. J Exp Med, 2017, 214(11):3219-3238.
[49]Cordero MD, Williams MR, Ryffel B. AMP-activated protein kinase regulation of the NLRP3 inflammasome during aging[J]. Trends Endocrinol Metab, 2018, 29(1):8-17.

备注/Memo

备注/Memo:
基金项目:延安市科学技术研究发展计划项目(2017KS-03)
作者单位:716000延安大学附属医院心内科
通信作者:高峰,E-mail:ydfygf@163.com
更新日期/Last Update: 2020-01-15